Hospira, Inc., and Mayne Pharma Limited, In the Matter of

Last Updated:
In the Matter of Hospira, Inc. and Mayne Pharma Limited
FTC Matter/File Number:

0710002

Docket Number:

C-4182

Enforcement Type:

Part 2 Consents

Case Summary

The consent order settles charges that Hospira Inc.’s proposed $2 billion acquisition of rival drug manufacturer Mayne Pharma Ltd. would likely reduce competition in the following products: hydromorphone hydrochloride (hydromorphone), nalbuphine hydrochloride (nalbuphine), morphine sulfate (morphine), preservative-free morphine, and deferoxamine mesylate (deferoxamine).  In settling the Commission’s charges, the companies agreed to divest to Barr Pharmaceuticals, Inc. (Barr), within 10 days of the acquisition, Mayne’s rights and assets related to the relevant products.